#Perfusion System Market 2030

[neha24blog]

Perfusion System Market Trends Analysis Report By Application, Region And Forecast To 2030 : Grand View Research Inc.

Perfusion System Market Trends Analysis Report By Application, Region And Forecast To 2030 : Grand View Research Inc.

San Francisco, 21 Nov 2022: The Report Perfusion System Market Size, Share & Trends Analysis Report By Application (Cardiopulmonary Perfusion System, Cell Perfusion System, Ex-vivo Organ Perfusion System), By Region, And Segment Forecasts, 2022 – 2030 The global perfusion system market size is projected to reach USD 1.54 billion by 2030, according to a new report by Grand View Research, Inc.…

[bhushans]

Cardiac Surgery Devices Market Insights: What to Expect by 2034

The  cardiac surgery devices market is on track for notable growth, with a projected valuation of USD 1.7 billion by the end of 2022. Over the next decade, the market is expected to expand at a compound annual growth rate (CAGR) of 3.6%, reaching approximately USD 2.4 billion by 2032. This growth is primarily fueled by the increasing prevalence of cardiovascular diseases worldwide.

In 2021, perfusion disposables led the market, commanding a significant demand share of about 59.1%. These disposables are critical components used in open-heart procedures to address various structural defects in the cardiovascular system. Key applications include coronary artery bypass grafting, congenital heart defect repairs, abdominal aortic aneurysm repair, ventricular remodeling, and cardiac assist device implantation.

Cardiac surgery devices, such as heart-lung machines, play an essential role in cardiothoracic surgery, particularly for performing cardiopulmonary bypasses. As cardiovascular diseases continue to pose major health challenges globally, the demand for these devices is expected to rise, driving market growth.

Get your PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4602

By encouraging the use of perfusion disposables, the market for cardiac surgical instruments is anticipated to gain from the rising popularity of heart-lung machine tables. Cardiovascular disease is the leading cause of death in the United States, contributing to over one-third of all deaths worldwide and 17 percent of US healthcare costs. According to American Heart Association forecasts, by 2030, 40% of Americans will suffer from cardiovascular sickness, with a direct cost of over $820 billion.

Well-developed Medical Infrastructure Makes North America Keep its Crown

North America has a world-class medical infrastructure coupled with a population that is rapidly ageing and suffering from cardiopulmonary disorders.

This combination all but ensures that the region is larger than both Western Europe and APEJ combined in the year 2017 with a value of just under US$ 555 Million.

North America is on track to witness a CAGR of 4.1% for the period 2017 to 2027 that should see the market in the region touch US$ 830 Million by end 2027.

Most new developments are centred in North America and its high acceptance of modern technology make it an extremely lucrative region in the global cardiac surgery devices market.

Minimally Invasive Surgery Gaining Traction in Cardiac Surgery Devices Market

Coronary artery bypass grafting is anticipated to be the largest contributor in the cardiac surgery devices market by procedure in 2017 and it is unlikely to cede this position anytime soon.

However, modern advancements in cardiopulmonary bypass techniques, surgical approaches and incisions have made minimally invasive surgery increasingly popular in recent times.

Minimally invasive surgery has the advantage of reduced surgical trauma and decreased pain and this is anticipated to propel the cardiac surgery devices market in the long term.

In terms of CAGR these two segments hold the top position in the global cardiac surgery devices market, with coronary artery bypass grafting recording a value CAGR of 3.5% and minimally invasive surgery registering a 4.1% CAGR in terms of revenue during the forecast period.

Focus on Hospitals over Ambulatory Surgical Centres in the Cardiac Surgery Devices Market

The hospitals segment is larger than the ambulatory surgical centres segment by end user in the cardiac surgery devices market and this trend is predicted to continue for the foreseeable future.

An attractiveness index of 1.1 and a market opportunity of almost US$ 1.2 Bn by 2027 end should make all major companies actively target the hospitals end user segment in the cardiac surgery devices market.

Company Dashboard:

The companies actively involved in the global cardiac surgery devices market that have been profiled in the report include Biotronik, Braile Biomedica, Cook Medical Inc., Estech, Abiomed, Smith Medical, MicroPort Scientific Corporation, Edwards Lifesciences Corporation, Angiodynamics, Teleflex Incorporated, C. R. Bard, Inc, B. Braun Melsungen AG, Getinge-Maquet Germany Holding GmbH, Terumo Corporation, LivaNova PLC, Lepu Medical technology Co ltd., Boston Scientific Corporation, Medtronic, and Abbott Laboratories.

Important takeaways:

The increasing preference for minimally invasive surgical procedures is one of the recent trends seen in the cardiac surgery devices market.

In the last decade, minimally invasive cardiothoracic surgery has grown by leaps and bounds mainly because of the reduced pain and surgical trauma after this procedure.

Even though coronary artery bypass grafting is much larger at present, key stakeholders are advised to focus on minimally invasive procedures as patients will almost certainly prefer this form of treatment.

In addition to this, the beating heart surgery system type could see widespread adoption in the days ahead.

Key Segments:

By Product:

Heart Lung Machine

Breathing Heart Surgery Systems

Stabilisers

Positioners

Catheters

Ablation Catheter

Drainage Catheter

Perfusion Disposables

Oxygenators

Centrifugal Pumps

Cardioplegia Delivery System

By End User:

Hospitals

Ambulatory Surgical Centres

By Procedure:

Coronary Artery Bypass Grafting

On pump CABG

Off pump CABG

Minimally Invasive Surgery

By Region:

North America

Latin America

Western Europe

Eastern Europe

APEJ

Japan

MEA

[chiragreportprime]

Regional Oximeter Market Size, Type, segmentation, growth and forecast 2023-2030

Regional Oximeter Market

The Regional Oximeter Market is expected to grow from USD 2.40 Billion in 2022 to USD 3.80 Billion by 2030, at a CAGR of 5.90% during the forecast period.

Get the Sample Report: https://www.reportprime.com/enquiry/sample-report/10212

Regional Oximeter Market Size

The Regional Oximeter market research report analyzes the market segment based on type (reusable sensor, disposable sensor), application (hospital, clinic, others), and region (North America, Asia Pacific, Middle East, Africa, Australia, and Europe). The major market players include GE, Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Nonin Medical Inc., Smiths Medical, Spacelabs Healthcare Inc., Nihon Kohden Corporation, Halma Plc, Contec Medical Systems Co. Ltd., Medtronic plc, Opto Circuits India Ltd., and Edwards Lifesciences Corporation. The report also provides information on regulatory and legal factors specific to market conditions. Regional oximeters are instrumental in measuring peripheral tissue saturation, and are an essential tool in the operating room, critical care unit, and outpatient settings. The report indicates that the growth of this market can be attributed to factors like the rise in surgical procedures, advancements in pulse oximetry technology, and the increasing prevalence of respiratory diseases. However, the regulatory and legal factors specific to market conditions such as product safety and efficacy, reimbursement policies, and intellectual property rights can impact the growth of the regional oximeter market.

Regional Oximeter Market Key Player

GE

Koninklijke Philips N.V.

Drägerwerk AG & Co. KGaA

Nonin Medical Inc.

Smiths Medical

Buy Now & Get Exclusive Discount on this https://www.reportprime.com/enquiry/request-discount/10212

Regional Oximeter Market Segment Analysis

The Regional Oximeter target market is primarily driven by factors such as the rising prevalence of respiratory disorders, such as chronic obstructive pulmonary disease (COPD), and the increasing demand for non-invasive monitoring devices. Additionally, the increasing geriatric population and the growing adoption of remote patient monitoring technologies are also expected to boost the demand for regional oximeters. The global market for regional oximeters is projected to grow significantly over the next few years due to the increasing need for continuous and accurate monitoring of patients in critical care settings.

The latest trends in the regional oximeter market include the growing adoption of wireless and portable devices, the emergence of new technologies such as pulse oximetry, and the increasing popularity of remote monitoring technologies. These trends are expected to drive the growth of the market further, as they provide healthcare professionals with accurate and reliable data about a patient's condition, allowing for better diagnosis and treatment.

However, the market for regional oximeters also faces several major challenges, including the high cost of devices and limited accuracy in monitoring certain patient populations, such as those with dark skin tones or low perfusion. Additionally, the availability of non-invasive monitoring alternatives, such as capnography, may also limit the growth potential of the regional oximeter market.

Overall, the main findings of the report suggest that the potential for growth in the regional oximeter market remains strong, despite these challenges. To capitalize on this potential, companies in the industry should focus on developing more accurate and cost-effective products, as well as improving the usability and compatibility of their devices with existing healthcare systems. Additionally, investing in research and development to improve the accuracy of regional oximeters in monitoring certain patient populations could also provide significant growth opportunities.

This report covers impact on COVID-19 and Russia-Ukraine wars in detail.

Purchase This Report: https://www.reportprime.com/checkout?id=10212&price=3590

Market Segmentation (by Application):

Hospital

Clinic

Others

Information is sourced from www.reportprime.com

[priyanshisingh]

Biopharmaceutical Contract Manufacturing Market Is Expected To Generate A Revenue Of USD 17.9 Billion By 2030

The latest market report published by Credence Research, Inc. “Global Biopharmaceutical Contract Manufacturing Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global biopharmaceutical contract manufacturing market has grown steadily in recent years. It is expected to grow at a CAGR of 9.5% between 2023 and 2030. The market was valued at USD 8.8 Billion in 2022 and is expected to reach USD 17.9 Billion in 2030.

The biopharmaceutical contract manufacturing market is experiencing significant growth, and key trends are shaping its trajectory. One of the main factors driving this expansion is the increasing demand for specialized expertise in drug development and production. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to contract manufacturers who possess advanced technical know-how and state-of-the-art facilities. Another notable trend is the rising number of partnerships between biopharmaceutical companies and contract manufacturers, fostering innovation through collaboration. This allows both parties to combine their strengths, leading to faster product commercialization and improved patient outcomes. Additionally, advancements in technology have revolutionized the biopharmaceutical sector, enabling more efficient manufacturing processes that can handle complex biological products such as cell therapies or gene therapies.

The biopharmaceutical industry has been witnessing substantial growth due to advancements in biotechnology and the rising prevalence of chronic diseases worldwide. The development of complex biologics and personalized medicine has further fueled the demand for efficient contract manufacturing services.

Outsourcing Trend Boosting Market Expansion

The trend of outsourcing biopharmaceutical manufacturing activities has gained traction in recent years, as pharmaceutical companies seek to focus on their core competencies, such as research and development, while relying on specialized contract manufacturing organizations (CMOs) for manufacturing and production. Outsourcing allows companies to reduce capital investment and operational costs while accessing state-of-the-art facilities and expertise of established CMOs.

Key Market Drivers and Opportunities

The Biopharmaceuticals Contract Manufacturing Market is driven by several key factors, including:

1. Rising Demand for Biologics: The increasing demand for biologics, including monoclonal antibodies, recombinant proteins, and vaccines, has stimulated the need for contract manufacturing services. Biologics offer targeted therapies and novel treatment options for various diseases, prompting pharmaceutical companies to outsource manufacturing to meet the rising demand.

2. Growing Complexity of Biopharmaceuticals: The complexity of biopharmaceutical products requires specialized manufacturing capabilities and stringent quality control measures. Contract manufacturing organizations equipped with advanced technology and regulatory expertise are better positioned to produce these complex biologics efficiently.

3. Advancements in Bioprocessing Technology: Continuous innovations in bioprocessing technologies, such as single-use systems, perfusion bioreactors, and cell culture media, have enhanced the productivity and cost-effectiveness of biopharmaceutical manufacturing. CMOs adopting these advanced technologies gain a competitive advantage in the market.

4. Expansion of Biopharmaceutical Pipelines: The robust growth of biopharmaceutical pipelines, driven by extensive research and development activities, has led to an increased need for contract manufacturing services. As pharmaceutical companies seek to expedite the development and commercialization of their products, outsourcing manufacturing processes becomes a strategic option.

5. Growing Biosimilars Market: The emergence of biosimilars as cost-effective alternatives to originator biologics has boosted their adoption worldwide. Contract manufacturing organizations play a crucial role in the production of biosimilars, contributing to the market growth.

Browse 190 pages report Biopharmaceutical Contract Manufacturing Market By Source (Mammalian, Non-mammalian) By Service (Process Development, Downstream., Upstream, Fill & Finish Operations, Analytical & QC studies, Packaging) - Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/biopharmaceutical-contract-manufacturing-market

North America Leads the Market

North America holds the largest share in the Biopharmaceuticals Contract Manufacturing Market and is expected to maintain its dominance during the forecast period. The region's well-established biopharmaceutical industry, favorable regulatory environment, and significant investments in biotechnology research contribute to its market leadership.

Asia Pacific: A Lucrative Market

Asia Pacific is emerging as a lucrative market for biopharmaceutical contract manufacturing services. The region offers cost-effective manufacturing solutions and a large pool of skilled workforce, making it an attractive destination for outsourcing biopharmaceutical production.

Conclusion

The Biopharmaceuticals Contract Manufacturing Market is witnessing significant growth, driven by the increasing trend of outsourcing and the growing demand for biologics. As pharmaceutical companies focus on innovation and pipeline expansion, contract manufacturing organizations play a crucial role in meeting the manufacturing needs of the industry. North America remains a dominant market, while Asia Pacific presents promising growth opportunities.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Biopharmaceutical Contract Manufacturing Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Biopharmaceutical Contract Manufacturing Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/biopharmaceutical-contract-manufacturing-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/temperature-sensitive-packaging-market

Related Report: https://www.credenceresearch.com/report/seaweed-coated-carton-market

Browse Our Blog: https://www.linkedin.com/pulse/biopharmaceutical-contract-manufacturing-market-share-priyanshi-singh

Browse Our Blog: https://tealfeed.com/biopharmaceutical-contract-manufacturing-market-size-worth-5q5ef

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[rohit0024]

Perfusion System Market Size Worth $1.54 Billion By 2030

Perfusion System Market Growth & Trends The global perfusion system market size is projected to reach USD 1.54 billion by 2030, according to a new report by Grand View Research, Inc. Furthermore, the market is projected to advance at a CAGR of 4.7% from 2022 to 2030. Factors such as the growing prevalence of chronic diseases and the rise in the number of organ transplants and multiple organ…

[neha24blog]

Perfusion Systems Market Demand By Application, Region And Forecast To 2030: Grand View Research Inc.

San Francisco, 29 Aug 2024: The Report Perfusion Systems Market Size, Share & Trends Analysis Report By Application (Cardiopulmonary Perfusion System, Cell Perfusion System), By Region (North America, Europe), And Segment Forecasts, 2024 – 2030 The global perfusion systems market size is projected to reach USD 1.55 billion by 2030, according to a new report by Grand View Research, Inc.…

[adityarana1687-blog]

Coronary Heart Disease Diagnostic Imaging Devices Market Predicted To Surpass $2.96 Billion By 2030

The global coronary heart disease diagnostic imaging devices market is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.9% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.

Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.

The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively. However, diabetic and hypertensive patients witnessed a severe risk of CVD ultimately leading to death. Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.

Request a free sample copy or view report summary: Coronary Heart Disease Diagnostic Imaging Devices Market Report

Coronary Heart Disease Imaging Devices Market Report Highlights

Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.

Computed tomography held the highest CAGR of 7.6% due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.

Asia Pacific is anticipated to be growing at the fastest CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.

Coronary Heart Disease Imaging Devices Market Segmentation

Grand View Research has segmented the global coronary heart disease imaging devices market based on modality and region:

Modality Outlook (Revenue, USD Million,2018 - 2030)

Computed Tomography

X rays

Ultrasound

Magnetic Resonance Imaging

Nuclear Medicine

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

U.K.

Germany

France

Italy

Spain

Norway

Denmark

Netherlands

Poland

Austria

Switzerland

Japan

China

India

South Korea

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

List of Key Players in Coronary Heart Disease Imaging Devices Market

GE

Fujifilm

Siemens

Toshiba

Hitachi

Koninklijke Phillips

Canon Medical Systems Corporation

Analogic Corp

[rootsanalysis-blog]

The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

 Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions. 

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

 To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/310/request-sample.html

 The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

§  More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs

§  An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters

§  A detailed assessment of the current market landscape of BBB penetrant drugs.

§  Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.

§  An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.

§  Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.

§  An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.

§  An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.

§  An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).

§  An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.

§  An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.

§  An assessment of the most commonly targeted disorders affecting the central nervous system  , shortlisted on the basis of number of BBB penetrant drugs in development.

§  A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.

§  A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.

§  An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :

§  Type of Payment Model Adopted

§  Upfront payments

§  Milestone payments

 §  Type of Molecule

§  Small Molecules

§  Biologics

 §  Target Disease Indication

§  Brain Metastases in Breast Cancer

§  Glioblastoma Multiforme

§  Hunter Syndrome

§  Hurler Syndrome

 §  Leading Technology Platforms

§  G®-Technology

§  J-Brain Cargo® Technology

§  LRP-1 Technology

§  Trojan Horse Technology

 §  Leading Drug Developers

§  2-BBB

§  Angiochem

§  ArmaGen

§  JCR Pharmaceuticals

 §  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

 Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))

§  Frank S Walsh (Chief Executive Officer and Founder, Ossianix)

§  Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)

§  Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)

§  Mathias Schmidt (Chief Executive Officer, ArmaGen)

§  Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)

§  Xavier Rivero (Chief Operating Officer, Sagetis Biotech)

§  Carole Desseaux (Head of Clinical Affairs, CarThera)

§  Jamal Temsamani (Head of Drug Development, Vect-Horus)

§  Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

 Key companies covered in the report

§  Angiochem

§  ArmaGen

§  BioArctic

§  Cyclenium Pharma

§  Denali Therapeutics

§  ICB International

§  Iproteos

§  JCR Pharmaceuticals

§  Lauren Sciences

§  Medesis Pharma

§  Ossianix

§  Vect-Horus

 For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.       Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

2.       DNA-Encoded Libraries: Platforms and Services Market

3.       Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

  Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[rohit0024]

Perfusion System Market Size Worth $1.54 Billion By 2030

Perfusion System Market Growth & Trends The global perfusion system market size is projected to reach USD 1.54 billion by 2030, according to a new report by Grand View Research, Inc. Furthermore, the market is projected to advance at a CAGR of 4.7% from 2022 to 2030. Factors such as the growing prevalence of chronic diseases and the rise in the number of organ transplants and multiple organ…